中国临床康复2004，Vol.8Issue(34)：7872-7873,2.
川芎嗪与噻氯匹定对缺血性脑卒中患者血小板聚集性影响的比较
Comparison of the impacts on inhibition of platelet aggregation in patients with ischemic cerebral apoplexy between Ligustrazine and Ticlopidine
吴旭1
作者信息
- 1. 武汉大学人民医院神经内科,湖北省,武汉市,430060
- 折叠
摘要
Abstract
BACKGROUND: Ligustrazine and Ticlopidine can be used to prevent the onset of cerebral apoplexy in high-risk population, the relapse of moderate and severe cerebral apoplexy survivors, or the complication of myocardial infarct. Although Ligustrazine has less adverse effects than Ticlopidine, the effects of both medications should be evaluated from many aspects.OBJECTIVE: To compare the impacts of Ligustrazine and Ticlopidine on platelet aggregation in ischemic cerebral apoplexy patients to provide an objective gist for the medication in cerebral apoplexy prevention. DESIGN: A randomized controlled trial.SETTING: Department of Neurology of the People' s Hospital of Wuhan University.PARTICIPANTS: A total of 56 patients selected from 112 confirmed ischemic cerebral apoplexy patients who were admitted by the People' s Hospital of Wuhan University during February 2001 to May 2002 were randomly divided into group I(Ligustrazine intravenous instilment) and group Ⅱ(Ticlopidine intravenous instilment) with 28 patients each.INTERVENTIONS: Experiment in vitro: fasting venous blood was taken from the patient for assaying the curve of platelet aggregation by turbridimetric assay. Clinical trial: patients in group Ⅰ received 300 mg/day of Ligustrasine through intravenous instilment while patients in group Ⅱ received250 mg/day of Ticlopidine through intravenous instilment. The therapeutic course was 1 month. Platelet aggregation curve was assayed after therapy.MAIN OUTCOME MEASURES: ① the impacts of the medications on the inhibitive rate of platelet aggregation in patients with ischemic cerebral apoplexy; ② changes in the maximum platelet aggregation rate before and after therapy in patients of both groups.RESULTS: Both Ticlopidine and Lignstrazine could quite strongly inhibit plate aggregation. Ticlopidine had slightly stronger effects than that of Ligustrazine with no statistical significance ( P ＞ 0. 05) . The maximum platelet aggregation rate before and after therapy in both Group Ⅰ and GroupⅡ were(58.6± 10.7), (37.8±12.2)%, and(60.2 ± 10.9), (34.6 ±13.6)% respectively. There were significant differences between before and after therapy in both groups ( t = 6.78, 7.77, P ＜ 0. 01 ).CONCLUSION: Both Lignstrazine and Ticlopidine can inhibit platelet aggregation in both experiment in vitro and clinical trial with corresponding effects. No special adverse effects and side effects occur.关键词
脑血管意外/川芎嗪/血小板聚集抑制分类
医药卫生引用本文复制引用
吴旭..川芎嗪与噻氯匹定对缺血性脑卒中患者血小板聚集性影响的比较[J].中国临床康复,2004,8(34):7872-7873,2.
